MediWound Ltd.
MDWD$183M
Micro CapNASDAQMedicinal Chemicals & Botanical Products🇺🇸North AmericaYAVNE111 employees
Drugs in Pipeline
8
Phase 3 Programs
4
Upcoming Catalysts
2
Next Catalyst
Aug 13, 2026
7wMarket Overview
Stock performance and key metrics
MDWD News
Catalyst Timeline
2 upcoming, 0 past
Drug Pipeline
DGD
Burn
Gel Vehicle
Thermal Burns
EscharEx (EX-03)
Venous Leg Ulcer (VLU)
NexoBrid
Thermal Burns
EscharEx
Hard to Heal Wounds
EscharEx (5% EX-02 formulation)
Venous Leg Ulcer
EscharEx (EX-02 formulation)
Venous Leg Ulcer
EscharEx 5% (EX-02 formulation)
Superficial Basal Cell Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
DGD | Phase 3 | Burn | - | - |
Gel Vehicle | Phase 3 | Thermal Burns | - | - |
EscharEx (EX-03) | Phase 3 | Venous Leg Ulcer (VLU) | - | - |
NexoBrid | Phase 3 | Thermal Burns | - | - |
EscharEx | Phase 2 | Hard to Heal Wounds | - | - |
EscharEx (5% EX-02 formulation) | Phase 2 | Venous Leg Ulcer | - | - |
EscharEx (EX-02 formulation) | Phase 2 | Venous Leg Ulcer | - | - |
EscharEx 5% (EX-02 formulation) | Phase 2 | Superficial Basal Cell Carcinoma | - | - |
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply